Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Símbolo de cotizaciónBJDX
Nombre de la empresaBluejay Diagnostics Inc
Fecha de salida a bolsaNov 10, 2021
Director ejecutivoMr. Neil (Indranil) Dey
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 10
Dirección360 Massachusetts Avenue, Suite 203
CiudadACTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01720
Teléfono19786310152
Sitio Webhttps://bluejaydx.com/
Símbolo de cotizaciónBJDX
Fecha de salida a bolsaNov 10, 2021
Director ejecutivoMr. Neil (Indranil) Dey
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos